{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical Stock Hits Day Low of $18.29 Amid Price Pressure
Ultragenyx Pharmaceutical, Inc. has faced notable stock volatility, hitting an intraday low and showing significant declines over various time frames, including year-to-date and one-year performances. The company, with a market capitalization of approximately USD 2,108 million, faces challenges indicated by negative financial metrics.
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance
Ultragenyx Pharmaceutical, Inc. has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company, with a market capitalization of USD 2,108 million, struggles with profitability, negative book value, and a high Debt to EBITDA ratio, indicating ongoing operational challenges.
Ultragenyx Pharmaceutical Hits Day Low at $19.86 Amid Price Pressure
Ultragenyx Pharmaceutical, Inc. has faced notable stock volatility, declining significantly today and over the past week and month. The company has underperformed the S&P 500, with substantial year-to-date and one-year losses. Financial metrics indicate challenges in growth and debt management, raising concerns about its market position.
Ultragenyx Stock Gaps Down 5% Amid Weak Start and Market Concerns
Ultragenyx Pharmaceutical, Inc. opened with a notable loss, reflecting a broader trend in its stock performance. Over the past month, the company has seen a decline, contrasting with the S&P 500. Technical indicators present a mixed outlook, while its market capitalization is around USD 2,108 million.
Ultragenyx Pharmaceutical Hits Day High with Strong 8.12% Intraday Surge
Ultragenyx Pharmaceutical, Inc. saw a notable stock increase on September 30, 2025, reaching an intraday high. Despite recent gains, the company has faced a significant one-year decline. Positive quarterly results and strong institutional backing contrast with ongoing risks, including negative EBITDA and a high debt-to-equity ratio.
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics
Ultragenyx Pharmaceutical, Inc. has recently revised its evaluation amid challenging market conditions. The stock price has increased from the previous close, but the company has experienced significant declines over the past year and five years, contrasting sharply with broader market performance. Technical indicators show mixed signals.
Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?
As of September 26, 2025, Ultragenyx Pharmaceutical, Inc. is in a mildly bearish trend, indicated by mixed technical signals and underperformance against the S&P 500, with year-to-date and one-year returns of -30.88% and -47.34%, respectively.
Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?
As of September 26, 2025, Ultragenyx Pharmaceutical, Inc. is in a mildly bearish trend, with mixed technical indicators and a year-to-date return of -30.88%, significantly underperforming the S&P 500's 12.96%.
Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?
As of September 2, 2025, Ultragenyx Pharmaceutical, Inc. is in a mildly bearish trend, with daily moving averages and weekly indicators signaling bearish conditions, while the stock has significantly underperformed the S&P 500 with a year-to-date return of -30.81%.
Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?
As of February 20, 2018, Ultragenyx Pharmaceutical, Inc. is considered risky and overvalued due to its high Price to Book Value of 24.36, negative EV to EBITDA of -8.10, and poor ROE of -377.52%, alongside significant underperformance against the S&P 500 with a YTD return of -30.81%.
Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?
As of February 20, 2018, Ultragenyx Pharmaceutical, Inc. is considered overvalued and risky due to significant negative financial ratios, including a Price to Book Value of 24.36 and a Return on Equity of -377.52%, alongside underperformance compared to the S&P 500.
Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?
As of June 2, 2025, Ultragenyx Pharmaceutical, Inc. shows a mildly bearish trend due to daily moving averages, despite some mildly bullish signals from weekly indicators, indicating mixed momentum overall.
Who are in the management team of Ultragenyx Pharmaceutical, Inc.?
As of March 2022, the management team of Ultragenyx Pharmaceutical, Inc. includes Mr. Daniel Welch as Independent Chairman and Dr. Emil Kakkis as President and CEO, along with several Independent Directors on the Board.
What does Ultragenyx Pharmaceutical, Inc. do?
Ultragenyx Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases. As of March 2025, it reported net sales of $139 million and a net loss of $151 million, with a market cap of approximately $3.47 billion.
How big is Ultragenyx Pharmaceutical, Inc.?
As of Jun 18, Ultragenyx Pharmaceutical, Inc. has a market capitalization of $3.47 billion, with net sales of $590.69 million and a net profit of -$549.58 million over the last four quarters. The company has shareholder's funds of $255.30 million and total assets of $1.50 billion as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
